Synthetic Biology Investors

We invest in B2B freight-tech, insurance-tech, synthetic biology, crop protection, energy, mobility, space, ed-tech, fintech, cybersecurity and homeopathic products.

Midven Limited is a private equity and venture capital firm specializing in investing in seed/start-up, early stage, growth, emerging growth, management buy-outs, and management buy-ins investments in small and medium sized enterprises. It does not invest in land, commodities, futures, shares, securities or other financial instruments; dealing in goods (other than in normal wholesale or retail trades); banking, insurance, money lending, debt factoring, hire-purchase financing and other financial activities; property development; farming, forestry or market gardening; operating or managing hotels or nursing or residential care homes. It also does not invest in ‘Restricted Sectors’ referred to in Article 32 of the EC Treaty. These include certain agricultural, and food related sectors and other sectors of which examples are synthetic fibres and yarns, motor vehicles and certain heavy industries. The firm does not provide grant funding. The firm is sector agnostic and prefers to invest in companies working in the field of technology, synthetic biology, manufacturing, engineering, medical, biotechnology, environmental technologies, information & communication technologies (ICT), digital media, saas, software, hardware, consumer, and service sectors. It invests in the Midlands region of United Kingdom with a focus on West Midlands, Shropshire, Staffordshire, Warwickshire, Worcestershire, Herefordshire, and the Metropolitan Borough of the West Midlands (Birmingham, Coventry and the Black Country) with exception for the Rainbow Seed Fund. It seeks to invest between $0.02 million and £5 million ($6.44 million) in its portfolio companies with a turnover up to €40 million ($45.06 million), net assets of no more than €27 million ($ 30.41 million), minimum EBITDA of £0.25 million ($0.35 million) and sale value maximum €40 million ($45.06 million) and debt investment value between £0.025 million ($0.03 million) to £2 million ($2.57 million). The firm invests through a mixture of ordinary equity shares and either redeemable preference shares, subordinated loans and quasi equity instruments. It always takes an equity stake in its portfolio companies and assumes role of board members or advisors. The firm seeks to exit from an investment within five to seven years through trade sale. Midven Limited was founded in 1990 and is based in Birmingham, United Kingdom with an additional office in London, United Kingdom and Harwell, United Kingdom. As of April 8, 2021, Midven Limited operates as a subsidiary of Future Planet Capital.

BioXClan is a venture capital firm specializing in biotechnology and synthetic biology companies from pre-seed to series A stages. The firm primarily invests in South Korea. BioXClan was founded in 2018 and is based in Seoul, South Korea.

Freigeist is a deep tech seed investor that backs European founders building global industry leaders in fields like AI, robotics, and synthetic biology with a hands-on, long-term approach.

Cesar Labs is the Accelerator and venture capital arm of C.E.S.A.R. The firm seeks to invest in seed, startup, early venture, mid venture and growth capital stages. The firm primarily invests in information technology and communication technology industries, as well as in retail, agriculture, health, education, editorial electronics, automotive, robotics and synthetic biology. Cesar Labs seeks to invest in Brazil. The firm invests up to R$ 0.03 million ($0.01 million) in each company. The firm prefers to hold a minority stake in its investments from 10% to 45%. Cesar Labs was founded in 1996 and is based in Pernambuco, Brazil.

AIR Capital is a venture capital firm specializing in pre-seed, series-A, seed/startup, early stage investments. The firm is sector and technology agnostic with focus on artificial intelligence, space tech, biotech, brain-computer interfaces, advanced organs-on-chip, nuclear fusion, blockchain, robotics, clean energy, advanced mobility, Internet of things, biomanufacturing, long-read sequencing, advanced computing, bioinformatics, electric vehicles, synthetic biology, foodtech, agtech and nanotech. The firm seeks to invest globally including US, Europe, Israel and Latin America. AIR Capital was founded in 2021 and is based in Buenos Aires, Argentina.

Lux Capital Management, LLC is a venture capital firm specializing in investments in series B, seed, early stage investments, special situations, and corporate spinouts. The firm primarily invests in energy, life sciences, biopharmaceutical, healthcare, and technology. It also seeks to invest in emerging technologies with a focus on digital health, advanced materials, drug delivery, therapeutics, mobile health, services, novel materials, energy, energy technology, wireless, semiconductors, nanotechnology, alternative energy technologies, and biotechnology sectors. The firm seeks to invest in deep technology such as machine learning, artificial intelligence, 3D printing, meta materials, robotics, and solid-state electronics. It also invests in augmented reality for the blind, neuro stimulation, age extending blood transplants, synthetic biology for industrial production, and Internet of things security for industrial and factory automation. The firm targets investing from $0.10 million and $100 million in a startup. The firm seeks to be a first institutional investor in its portfolio companies. It also provides follow on funding for future financing rounds. Lux Capital Management, LLC was founded in 2000 and is headquartered in New York, New York with an additional office in Menlo Park, California and San Diego, California.

MLS Capital Fund II (MLSCF II), co-managed by Spruce Capital Partners and Xeraya Capital, will invest the funds in a diversified portfolio of biogreentech companies at all stages of development. Biogreentech spans plant and animal agriculture; food, feed, and nutrition; bio-renewable chemicals and materials; and adjacent opportunities along the value chain, including “big data" analytics, robotics, production, harvesting and use of natural resources, and synthetic biology.

We invest in synthetic biology startups globally.

Olive Capital is a venture capital firm specializing in seed and early stage investments. The firm is sector agnostic with a focus on synthetic biology, software, and emergent platforms. The firm prefers to invest in Europe and the United States. Olive Capital is based in Switzerland.

We invest in high performance healthcare companies at the convergence of technology and biology. We focus on 4 key themes: connectivity, platform innovation, payments and deep technology. This includes: distributed care, virtual care, wearables, patient empowerment, artificial intelligence, mental health and holistic care solutions, chronic disease management, data analysis, alternative drug pricing, value-based care, care efficiency, preventative medicine, synthetic biology, nanotechnology, personalized medicine, gene editing, and more

Hedgewood Inc. formerly known as Aprilis Ventures is a private equity and venture capital firm specializing in direct and fund of fund investments in seed and early stage, buyouts and business acquisitions, secondaries and co-investments, mortgage and construction lending, mezzanine, specialty financing, litigation finance, invoice funding. The firm prefers to invest in technology with a focus on web-based businesses, online media, internet of things, wearable tech, internet infrastructure,software as a service, mobile apps, healthcare, health food, renewable energy, gaming, hosted applications, next generation networks, and storage. In venture capital it seeks to invest in consumer internet, SaaS/IoT, fintech, DTC Food & Consumer Health ProductsIt also seeks to invest in non-computer technologies, including cleantech, life sciences, and biotechnology. In health care sector it invests in rejuvenation biotech, wearable tech / digital therapeutics, synthetic biology / natural products. In real estate sector firm in invest in retail / office / multi-family, residential development, farmland / timberland. The firm seeks to invest in companies based in Canada and the U.S. with a focus on Toronto-Ottawa-Waterloo region. It may also consider investments abroad with the presence of a local investment partner. The firm may make minority investments in SME's and prefers to take majority stakes. Hedgewood Inc. is based in Toronto, Ontario.

At Future Ventures, we support passionate founders who are forging the future. For the past 24 years, we have backed the visionaries who push the boundaries of possibility and explore the frontier of the unknown. We focus on disruptive technology such as commercial space exploration, deep learning, quantum computing, robotics, AI, blockchain, sustainable transportation, synthetic biology and clean meat. In particular, we focus on seed and early-stage investments in trailblazing, purpose-driven entrepreneurs with unique ideas that have the potential to reinvent entire industries. As venture capitalists, the Future Ventures partners have led founding investments in several companies that had successful IPOs and others that were multi-billion dollar acquisitions. Some of our early VC investments include Memphis Meats, Mythic, Nervana, Planet, Skype, SpaceX, Tesla and Zoox. Here are some of those founding stories, representing $800 billion of aggregate value creation. You can follow us on Facebook, Twitter or our photo blog, listen to the long-form podcast interview, or read some of our thoughts on deep learning and manufacturing meat without animals, or browse our collection of Apollo space artifacts or rocketry gone wild.

Alturki Ventures is the Corporate Venture Capital arm of Alturki Holding, a leading business in the Kingdom of Saudi Arabia. Strengthened by the vast resources and extensive network and reach of the holding, Alturki Ventures identifies, invests and actively engages with companies and funds that are working with frontier technologies to drive positive change. Alturki Ventures identifies opportunities that have synergy with the holding’s core businesses and through research into global trends and robust due diligence, builds a pipeline of high potential investment opportunities. Our team of Venture Capital experts then accelerate growth by scaling business to new channels and customer segments. Alturki Ventures’ growing portfolio in the Middle East, Europe and the Americas, is comprised of companies that are changing the way we work and live across sectors such as Health tech, Logistics & Mobility tech, Education Tech, Fintech and Entertainment tech. They are empowering transformation in learning through AI and neuroscience, innovation in deep tech, digital health and synthetic biology, and applying machine learning to transfrom logistics, mobility & ecommerce for exceptional business and customer experiences. We are Empowering Transformation and building great businesses.

Recharge Capital, LLC is a venture capital firm specializing in incubation, early-stage, seed/startup, late-stage investments. The firm prefers to invest through growth capital transactions. The firm seeks to invest in fintech focusing on traditional and Web3, synthetic biology, digital asset infrastructure, fintech infrastructure, women's healthcare focusing on international fertility tourism, menstrual wellness, and women’s disease prevention and semiconductor technology sectors. It prefers investment in Southeast Asia, LatAm, Europe, and the Middle East. Recharge Capital, LLC was founded in 2016 is based in New York, New York with additional offices in Singapore, Singapore; Los Angeles, California and Hong Kong and Beijing, China.

We work with all deep science and deep technology ventures. We have an immediate emphasis on biotech, life sciences, Tools, diagnostics, engineered biology and synthetic biology.

Heartcore Capital is a European early-stage venture capital firm founded in 2007, with offices in Copenhagen, Stockholm, Berlin, and Paris. The firm has invested in over 100 startups across 13 countries, backing notable companies such as Tink, Neo4j, Boozt, Peakon, Seriously, and TravelPerk. Heartcore Capital focuses on sectors including the future of work, sustainability, synthetic biology, space tech, Web3, health and wellness, and travel tech. The firm typically invests between €1.5 million and €3 million in pre-seed, seed, and Series A/B funding stages. In December 2024, Heartcore Capital closed a €170 million Fund V, expanding its investment focus to include infrastructure, synthetic biology, and climate tech. Additionally, in December 2023, the firm launched its first Web3 fund, raising €15 million to invest in application layer protocols within the Web3 ecosystem.

A virtual accelerator for pioneers in FoodTech and Synthetic Biology, helping startups with market entry, fundraising, and technical communication.

Luminous Ventures is a London-based VC fund investing in Deep Tech with a focus on the application of artificial intelligence (AI), VR, AR, edge computing, robotics, quantum technologies and synthetic biology to healthcare, life science, nutrition, food and agriculture at Seed and Series A in Europe and North America. Since the inception of our first fund in 2015, we have deployed over £30 million in disruptive, deep-tech businesses.

UCB Ventures S.A. is a venture capital arm of UCB Pharma S.A. specializing in early stage and startups investments. The firm seeks to invest in innovative therapeutics and technology platforms; novel therapeutics modalities and platforms/assets that address novel biology. The firm seeks to invest in drug discovery, development and operations; breakthrough innovations in next-generation cell and gene therapy, regenerative medicine, cell and tissue homeostasis, Oligo-based and synthetic biology, and RNA modulation. The firm seeks to invest in US and Europe. UCB Ventures S.A. was founded in 2017 and is based in Brussels, Belgium with additional offices in London, United Kingdom; and Boston, Massachusetts.

Artis Ventures is a pioneering venture capital firm dedicated to investing in the convergence of technology, biology, and health—collectively termed "Tech Bio+Health." As the first fund globally to deploy capital in this transformative sector, Artis Ventures focuses on companies that leverage data, software, AI, machine learning, and deep learning to revolutionize human health and well-being. The firm coined and trademarked the term "TechBio" to signify a new era in medicine, where advancements in sequencing, computing, data management, and synthetic biology are reshaping healthcare approaches. With a global perspective, Artis Ventures aims to invest in scalable medical technologies that can improve health outcomes and cure diseases worldwide. Their portfolio includes data-driven life sciences companies addressing everyday health challenges through engineering-first approaches, personalized therapeutics, and efficient drug discovery.

Civilization Ventures is a venture capital firm founded in 2017 by Shahram Seyedin-Noor, a seasoned life sciences entrepreneur. The firm focuses on investing in transformative technologies across healthcare and biology, particularly in genomics, diagnostics, synthetic biology, and digital health. With over $100 million in capital under management, Civilization Ventures has partnered with more than 60 innovative companies. Their investment approach, termed "mentor capital," emphasizes supporting founders to reach their full potential without replacing them. The firm also runs a Fellowship program to train PhDs and MDs to become future entrepreneurs in the life sciences sector.

We invest in revenue-generating ventures with growth momentum. We are sector agnostic, but have preference for the following themes: ▪ Technology (productivity, innovation) – software, Ai, AR, VR, robotics, space, fintech, etc.. ▪ Planet (sustainability) – clean energy, mobility, smart clean and sustainable cities, circular economy, etc.. ▪ People (health, wellness, society) – genomics, synthetic biology, food tech, consumer brands, education, digital democracy, security, etc..

Nuance Capital Limited is a venture capital firm specializing in seed, series A, series B, early stage and growth capital investments. The firm prefers to invest in deep tech ventures, which aim to solve large societal challenges like climate change - using emerging technologies like synthetic biology, artificial intelligence, advanced engineering, science, innovation, blockchain, advanced manufacturing, green energy, advanced materials, electronics and photonics, biotech and MedTech, robotics, deep A.I., IP, and blockchain or quantum technologies. It prefers to invest in New Zealand companies go global. Nuance Capital Limited is based in Auckland, New Zealand with an additional office in Auckland, New Zealand, Tauranga, New Zealand and Auckland, New Zealand.

Ten VC Management, LLC is a venture capital firm specializing in pre-seed & seed stage investments. The firm focuses on scalable biomanufacturing, next-generation chemistry, biotech/techbio, synthetic biology, AI/ML for life sciences, exponential automation, advanced manufacturing and supply chains, autonomous machines and applied systems, integrated compliance, fintech/insurtech 2.0, advanced computing, big data storage and processing, transformational development tools, cybersecurity and defense, energy transition, natural resources, profitable sustainability, longevity & space tech. Ten VC Management, LLC is headquartered in United States.